Fulcrum Therapeutics Inc To Review Initial FTX-6058 Data And Provide Program Update Call Transcript
Good morning. Welcome to the Fulcrum Therapeutics FTX-6058 in sickle cell disease Phase 1b trial update. (Operator Instructions) I'd like to turn the call over to Stephanie (inaudible) from Stern Investor Relations. Stephanie, please proceed.
Thank you, Norma. Good morning, and welcome to the Fulcrum Therapeutics conference call. Please be reminded that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include expressed or implied statements about our future expectations and plans and clinical development time lines, among others. While these forward-looking statements represent our views as of today, they should not be relied upon as representing our views in the future. We may update these statements in the future, but we are not taking on an obligation to do so.
Please refer to our most recent filings with the Securities and Exchange Commission for a discussion of certain risks and uncertainties associated with our business,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |